Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment and Prognosis for an Esthesioneuroblastoma over a 20-Year Period: Impact of Treatment Era

감각신경모세포종의 20년에 걸친 치료와 예후 분석: 치료 시기에 따른 차이

  • Song, Chang-Hoon (Departments of Radiation Oncology, Seoul National University College of Medicine) ;
  • Kim, Il-Han (Departments of Radiation Oncology, Seoul National University College of Medicine) ;
  • Wu, Hong-Gyun (Departments of Radiation Oncology, Seoul National University College of Medicine) ;
  • Kim, Dong-Wan (Departments of Internal Medicine, Seoul National University College of Medicine) ;
  • Rhee, Chae-Seo (Departments of Otorhinolaryngology and Head and Neck Surgery, Seoul National University College of Medicine)
  • 송창훈 (서울대학교 의과대학 방사선종양학교실) ;
  • 김일한 (서울대학교 의과대학 방사선종양학교실) ;
  • 우홍균 (서울대학교 의과대학 방사선종양학교실) ;
  • 김동완 (서울대학교 의과대학 내과학교실) ;
  • 이재서 (서울대학교 의과대학 이비인후학교실)
  • Received : 2009.09.29
  • Accepted : 2009.10.28
  • Published : 2009.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To report on the changes in the patterns of care and survival over time for esthesioneuroblastoma. Materials and Methods: We retrospectively analyzed 42 previously untreated and histologically confirmed esthesioneuroblastoma patients seen between March 1989 and June 2007. According to Kadish's classification, 3 patients (7%) were stage A, 6 (14%) at stage B, and 33 (79%) at stage C. Of the 33 Kadish C patients, 19 and 14 patients were treated from 1989 through 2000 and from 2001 through 2007, respectively. Treatment included surgical resection, radiotherapy, chemotherapy, or a combination of these methods. Chemotherapy was administered to 8 of 19 patients (42%) seen from 1989 through 2000, whereas all of the 14 patients seen from 2001 through 2007 received chemotherapy (p<0.001). No patient was treated by three-dimensional conformal radiotherapy (3D-CRT) from 1989 through 2000, however 8 of 14 patients (67%) seen from 2001 through 2007 underwent 3D-CRT (p<0.001). The median follow-up time for surviving patients was 6.5 years (range, 2.2~15.8 years). Results: The 5-year overall survival (OS) and progression-free survival (PFS) rates for the entire cohort were 53% and 39%, respectively. The 5-year OS was 100% for Kadish stages A or B and 39% for stage C (p=0.007). For patients with stage C disease who were treated from 1989 to 2000 and from 2001 to 2007, the 5-year OS rate was 26% and 59% (p=0.029), respectively and the corresponding 5-year PFS rate was 16% and 46% (p=0.001), respectively. Intraorbital extension and treatment era (1989~2000 vs. 2001~2007) were found as independent factors for OS and PFS in a multivariate analyses. Conclusion: The results of this study suggest that treatment era, which features a distinction in treatment modality and technique with the introduction of 3D-CRT, may be the cause of improved OS and PFS in Kadish stage C patients. To achieve better outcomes for patients with Kadish stage C, combined chemoradiotherapy, especially 3D-CRT, is recommended in addition to surgery.

목 적: 감각신경모세포종의 시대에 따른 치료방침과 생존율의 변화를 보고하고자 하였다. 대상 및 방법: 1989년 3월부터 2007년 6월 사이에 감각신경모세포종으로 진단을 받고 처음으로 치료를 받은 42명의 환자를 후향적으로 분석하였다. Kadish 병기에 따르면, 3명(7%)의 환자가 A병기, 6명(14%)의 환자가 B병기, 33명(79%)의 환자가 C병기였다. 33명의 C병기 환자 중, 19명은 1989년부터 2000년에, 14명은 2001년부터 2007년까지 치료 받았다. 치료는 수술, 방사선치료, 항앙화학요법 및 이들의 조합이었다. 1989년부터 2000년까지 치료를 받은 19명 중 8명(42%)이 항암화학요법을 받은 것에 비해, 2001년부터 2007년까지 치료를 받은 환자 14명은 모두 항암화학요법을 받았다(p<0.001). 삼차원입체조형방사선치료는 1989년부터 2000년에는 아무도 받지 않았으나 2001년부터 2007년도에 치료를 받은 14명 중 8명이 받았다(p<0.001). 생존환자에 대한 중앙 추적기간은 6.5년(범위, 2.2~15.8년)이었다. 결 과: 전체 환자에 대한 5년 생존율과 무진행생존율은 각각 53%와 39%였다. Kadish A혹은 B 환자의 5년 생존율은 100%이고 Kadish C병기의 5년 생존율은 39%였다(p=0.007). C병기 환자 중 1989년부터 2000년까지 치료받은 환자와 2001년부터 2007년까지 치료받은 환자의 5년 생존율은 각각 26%와 59%였다(p=0.029). 상응하는 5년 무진행생존율은 각각 16%와 46%였다(p=0.001). 다변량분석에서 안와내침범과 치료시대(1989~2000 vs. 2001~2007)가 생존율과 무진행생존율에 영향을 주는 독립인자로 확인되었다. 결 론: 본 연구의 결과 C병기 환자에서 삼차원입체조형방사선치료의 도입과 같은 치료방법과 기술의 진화를 반영하는 치료시기가 향상된 생존율과 무진행생존율의 원인이 될 수도 있음을 제시 하였다. C병기 환자에서 더 나은 결과를 얻기 위해서는 수술에 더하여 항암화학요법과 방사선치료 병용요법, 특히 삼차원입체조형방사선치료가 추천된다.

Keywords

References

  1. Ferlito A, Rinaldo A, Rhys-Evans PH. Contemporary clinical commentary: esthesioneuroblastoma: an update on management of the neck. Laryngoscope 2003;113:1935-1938 https://doi.org/10.1097/00005537-200311000-00015
  2. Simon JH, Zhen W, McCulloch TM, et al. Esthesioneuroblastoma:the University of Iowa experience 1978-1998. Laryngoscope 2001;111:488-493 https://doi.org/10.1097/00005537-200103000-00020
  3. Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma:a clinical analysis of 17 cases. Cancer 1976;37:1571-1576 https://doi.org/10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L
  4. Rinaldo A, Ferlito A, Shaha AR, Wei WI, Lund VJ. Esthesioneuroblastoma and cervical lymph node metastases:clinical and therapeutic implications. Acta Otolaryngol 2002;122:215-221 https://doi.org/10.1080/00016480252814261
  5. Resto VA, Eisele DW, Forastiere A, Zahurak M, Lee DJ, Westra WH. Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck 2000;22:550-558 https://doi.org/10.1002/1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0
  6. Constantinidis J, Steinhart H, Koch M, et al. Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000. Otolaryngol Head Neck Surg 2004;130:567-574 https://doi.org/10.1016/j.otohns.2003.10.010
  7. McElroy EA Jr, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery 1998;42:1023-1027 https://doi.org/10.1097/00006123-199805000-00040
  8. Koka VN, Julieron M, Bourhis J, et al. Aesthesioneuroblastoma. J Laryngol Otol 1998;112:628-633
  9. Wu HG, Kim IH. Treatment and results of olfactory neuroblastoma. J Korean Soc Ther Radiol Oncol 2000;18:177-181
  10. Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993;32:706-714 https://doi.org/10.1227/00006123-199305000-00002
  11. Levine PA, Gallagher R, Cantrell RW. Esthesioneuroblastoma:reflections of a 21-year experience. Laryngoscope 1999;109:1539-1543 https://doi.org/10.1097/00005537-199910000-00001
  12. McLean JN, Nunley SR, Klass C, Moore C, Muller S, Johnstone PA. Combined modality therapy of esthesioneuroblastoma. Otolaryngol Head Neck Surg 2007;136:998-1002 https://doi.org/10.1016/j.otohns.2006.11.051
  13. Chao KS, Kaplan C, Simpson JR, et al. Esthesioneuroblastoma: the impact of treatment modality. Head Neck 2001;23:749-757 https://doi.org/10.1002/hed.1107
  14. Spaulding CA, Kranyak MS, Constable WC, Stewart FM. Esthesioneuroblastoma: a comparison of two treatment eras. Int J Radiat Oncol Biol Phys 1988;15:581-590 https://doi.org/10.1016/0360-3016(88)90298-2
  15. Gruber G, Laedrach K, Baumert B, Caversaccio M, Raveh J, Greiner R. Esthesioneuroblastoma: irradiation alone and surgery alone are not enough. Int J Radiat Oncol Biol Phys 2002;54:486-491 https://doi.org/10.1016/S0360-3016(02)02941-3